TriGemX Bio Information

At TriGemX Bio, we are leveraging unique insights into neural signaling pathways and developing innovative medicines for the treatment of migraine. Our late-stage pipeline focuses on delivering an effective, easy to use, first-in-class medication. TriGemX Bio was founded by world-leading neuroscientists whose groundbreaking research into previously unexplored neural networks is now being carried forward by a team of experienced drug developers. Elismetrep, our lead asset being developed for the acute treatment of migraine, is in Phase 3.